Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.
Hanhan Yu, Jieping Wang, Mingyue Yin et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the effects of pharmacological and lifestyle interventions on body composition in patients with acquired hypothalamic obesity (aHO). Seven randomized controlled trials were analyzed, revealing that semaglutide led to sustained weight loss, while long-acting exenatide reduced fat mass. However, the overall evidence quality was low, particularly for body composition outcomes.
Key findings
- Semaglutide demonstrated sustained weight loss in patients with aHO.
- Long-acting exenatide reduced fat mass without significant lean mass loss.
- Tesomet was linked to reductions in both body weight and lean mass.
- Adverse events were mostly mild to moderate across interventions.
Why it matters
Understanding the effectiveness of pharmacological treatments in managing body composition can guide clinicians in optimizing care for patients with aHO. This review highlights the potential benefits and limitations of current interventions.
What to keep in mind
The review noted low certainty of evidence for key outcomes and substantial heterogeneity in interventions and measurements.